Kelly Ketcham passed from TTP one year ago. Kelly had three young, beautiful girls. She left behind loving family and friends that miss her more than words can say. Her family is organizing this t-shirt fundraiser in Kelly's honour to benefit Answering TTP Foundation.
Our heartfelt condolences to the family of the late Max Marin who died 10 days after being diagnosed with TTP. Max lived in Calgary, Alberta. He was a 45-year-old father, husband and well-known MMA trainer. Reports indicate that the TTP diagnosis was missed by the health clinic he visited initially. Only when his health deteriorated, and his family took him to the main hospital, was he diagnosed with TTP.
A research team at McMaster University has partnered with the International Society on Thrombosis and Haemostatis (ISTH) to create a clinical practice guideline on the diagnosis and management of TTP. The goal is to bring together a panel of expert researchers, clinicians, and patients to develop a set of recommendations on how to diagnose and treat TTP. Ultimately, this guideline will contribute to high quality care for patients with TTP around the world.
A healthcare research continues to recruit patients who have been diagnosed with acquired thrombotic thrombocytopenic purpura (aTTP) and live in the Continental US. This research focuses on understanding your experience with aTTP as well as evaluating a questionnaire designed for use in patients with aTTP. This research may help improve how the patients’ experience is accounted for in clinical trials for new treatments.
The Foundation would like to congratulate Dr. Zheng for being recognized with the 2017 Research Innovation in Scientific Excellence (RISE) Award form the American Association of Blood Banks (AABB). More about the award here. Dr.
On October 23, 2017 Sydney Kodatsky (Chair, Answering TTP Foundation) virtually presented to the Entrepreneurial innovation Bootcamp in Rare Diseases hosted in Leuven, Belgium. One of the organizers included TTP researcher Prof. Dr. Karen Vanhoorelbeke.
On Saturday, September 16, 2017, one hundred and fifty registered participants took part in the 7th annual Walk to Answer TTP Together. Participants walked internationally, in their local communities to help raise life-saving awareness and funds for TTP!
The Ohio State University TTP/aHUS face-to-face meeting was made available to non-local participants to join virtually. On Tuesday October 10th, Dr. Cataland welcomed special guest Dr. James N. George, of the University of Oklahoma Health Sciences Center.
October 2, 2017 ABLYNX "announced positive topline results from the Phase III HERCULES study with caplacizumab, the Company's anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)." View the full article.